PropertyValue
?:abstract
  • BACKGROUND: Secondary damage due to neurochemical and inflammatory changes in the penumbra in the first days after ischemic stroke contributes substantially to poor clinical outcome. In animal models, vagus nerve stimulation (VNS) inhibits these detrimental changes and thereby reduces tissue injury. The aim of this study is to investigate whether non-invasive cervical VNS (nVNS) in addition to the current standard treatment can improve penumbral recovery and limit final infarct volume. METHODS: NOVIS is a single-center prospective randomized clinical trial with blinded outcome assessment. One hundred fifty patients will be randomly allocated (1:1) within 12 h from clinical stroke onset to nVNS for 5 days in addition to standard treatment versus standard treatment alone. The primary endpoint is the final infarct volume on day 5 assessed with MRI. DISCUSSION: We hypothesize that nVNS will result in smaller final infarct volumes as compared to standard treatment due to improved penumbral recovery. The results of this study will be used to assess the viability and approach to power a larger trial to more definitively assess the clinical efficacy of nVNS after stroke. TRIAL REGISTRATION: ClinicalTrials.govNCT04050501. Registered on 8 August 2019
is ?:annotates of
?:creator
?:doi
?:doi
  • 10.1186/s13063-020-04794-1
?:journal
  • Trials
?:license
  • cc-by
?:pdf_json_files
  • document_parses/pdf_json/f7f8b26071712f1edb9d92b0d72350ed0cd069f8.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7586413.xml.json
?:pmcid
?:pmid
?:pmid
  • 33106174.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • NOn-invasive Vagus nerve stimulation in acute Ischemic Stroke (NOVIS): a study protocol for a randomized clinical trial
?:type
?:year
  • 2020-10-26

Metadata

Anon_0  
expand all